What serum profiling cannot establish about pathway use
A recent paper is titled “Serum metabolic profiling analysis of Gitelman syndrome using untargeted metabolomics” (PMID 42056734). The supplied metadata establishes the sample matrix and profiling scope, but gives no tracer, isotopologue, sampling schedule, or result. Serum abundance differences could reflect pathway activity, pool size, dietary input, tissue exchange, renal handling, or clearance. A flux claim would need a labeled substrate tied to a specific biochemical transition and a predicted labeled product. Serial sampling would then show whether product labeling appears with timing consistent with formation, while measurements in relevant additional matrices could help separate production from redistribution or loss. Until those design details are available, this source is best treated as a prompt to ask which reported associations concern metabolite abundance and which, if any, are supported by direct evidence of pathway use.
